EAQ222CD
|
ECOG-ACRIN
|
Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
EAY131
|
ECOG-ACRIN
|
Molecular Analysis for Therapy Choice (MATCH)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191
|
ECOG-ACRIN
|
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191-A3
|
Alliance
|
A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191-A6
|
ECOG-ACRIN
|
A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191-E4
|
ECOG-ACRIN
|
A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191-E5
|
ECOG-ACRIN
|
A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191-N2
|
ECOG-ACRIN
|
A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191-N4
|
ECOG-ACRIN
|
Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAY191-N5
|
ECOG-ACRIN
|
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|